Stem Cells http://www.peprotech.com/
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


First published online August 25, 2005
Stem Cells Vol. 24 No. 1 January 2006, pp. 105 -114
doi:10.1634/stemcells.2005-0062; www.StemCells.com
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-0062v1
24/1/105    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Drayer, A. L.
Right arrow Articles by Vellenga, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Drayer, A. L.
Right arrow Articles by Vellenga, E.

TISSUE-SPECIFIC STEM CELLS

Mammalian Target of Rapamycin Is Required for Thrombopoietin-Induced Proliferation of Megakaryocyte Progenitors

A. Lyndsay Drayer, Sandra G. M. Olthof, Edo Vellenga

Department of Research and Education, Sanquin Blood Bank, North East Region, Groningen, The Netherlands, and Division of Hematology, University Medical Centre Groningen, Groningen, The Netherlands

Key Words. Megakaryopoiesis • mTOR • TPO • CFU-Mk

Correspondence: A. Lyndsay Drayer, Ph.D., Sanquin Blood Bank, North East Region, P.O. Box 1191, 9701 BD, Groningen, The Netherlands. Telephone: +31-50-3611269; Fax: +31-50-3695556; e-mail: L.drayer{at}sanquin.nl

Thrombopoietin (TPO) is a potent regulator of megakaryopoiesis and stimulates megakaryocyte (MK) progenitor expansion and MK differentiation. In this study, we show that TPO induces activation of the mammalian target of rapamycin (mTOR) signaling pathway, which plays a central role in translational regulation and is required for proliferation of MO7e cells and primary human MK progenitors. Treatment of MO7e cells, human CD34+, and primary MK cells with the mTOR inhibitor rapamycin inhibits TPO-induced cell cycling by reducing cells in S phase and blocking cells in G0/G1. Rapamycin markedly inhibits the clonogenic growth of MK progenitors with high proliferative capacity but does not reduce the formation of small MK colonies. Addition of rapamycin to MK suspension cultures reduces the number of MK cells, but inhibition of mTOR does not significantly affect expression of glycoproteins IIb/IIIa (CD41) and glycoprotein Ib (CD42), nuclear polyploidization levels, cell size, or cell survival. The downstream effectors of mTOR, p70 S6 kinase (S6K) and 4E-binding protein 1 (4E-BP1), are phosphorylated by TPO in a rapamycin- and LY294002-sensitive manner. Part of the effect of the phosphatidyl inositol 3-kinase pathway in regulating megakaryopoiesis may be mediated by the mTOR/S6K/4E-BP1 pathway. In conclusion, these data demonstrate that the mTOR pathway is activated by TPO and plays a critical role in regulating proliferation of MK progenitors, without affecting differentiation or cell survival.




This article has been cited by other articles:


Home page
Stem CellsHome page
S. G. Olthof, S. Fatrai, A. L. Drayer, M. R. Tyl, E. Vellenga, and J. J. Schuringa
Downregulation of Signal Transducer and Activator of Transcription 5 (STAT5) in CD34+ Cells Promotes Megakaryocytic Development, Whereas Activation of STAT5 Drives Erythropoiesis
Stem Cells, July 1, 2008; 26(7): 1732 - 1742.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS

Copyright © 2006 by AlphaMed Press.